Jazz Pharmaceuticals (JAZZ) Capital Expenditures (2010 - 2026)

Jazz Pharmaceuticals has reported Capital Expenditures for 17 years, with the latest figure at $77.2 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 455.4% year-over-year to $77.2 million; the trailing twelve-month figure through Mar 2026 stood at $122.1 million (up 1644.6% YoY), and the FY2025 full-year result was $58.8 million, changed N/A from the prior year.
• Capital Expenditures for Q1 2026 stood at $77.2 million, up from $16.7 million in the prior quarter.
• The five-year high for Capital Expenditures was $844.2 million in Q2 2025, with the low at -$816.0 million in Q3 2025.
• Average Capital Expenditures over 5 years is $11.8 million, with a median of $8.2 million recorded in 2022.
• Peak annual rise in Capital Expenditures reached 11804.57% in 2025, while the deepest fall reached 5730.87% in 2025.
• Tracing JAZZ's Capital Expenditures over 5 years: stood at $9.4 million in 2022, then climbed by 7.72% to $10.1 million in 2023, then sank by 238.54% to -$14.0 million in 2024, then surged by 219.54% to $16.7 million in 2025, then surged by 361.47% to $77.2 million in 2026.
• The last three Capital Expenditures figures came in at $77.2 million (Q1 2026), $16.7 million (Q4 2025), and -$816.0 million (Q3 2025), per Business Quant data.

Peer Comparison